How has the Orphan Regulation contributed to addressing unmet medical needs for rare disease?
Is it time for a revision of the OMP Regulation?
What can be done to support faster more equitable access to orphan medicines to patients?
How can our regulatory system help new medicines get to patients faster?
What are the development challenges specific to orphan medicines?
How are R&D decisions taken?
40% of new medicines in the pipeline are orphan medicines. What does the future hold?